We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study (PROVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01162356
Recruitment Status : Completed
First Posted : July 14, 2010
Last Update Posted : February 23, 2017
Information provided by (Responsible Party):
Stephen J. Kim, MD, Vanderbilt University

Brief Summary:

Since the introduction of vitrectomy in 1971, this procedure has become the third most frequently performed ophthalmic surgery. Approximately 225,000 vitrectomies are performed annually in the United States and indications continue to expand. Known long-term complications of vitrectomy are relatively few and include retinal detachment and cataract formation. Although much has been written in the literature concerning acute rises in intraocular pressure (IOP) in the immediate postoperative period, there is surprisingly little information on long term IOP outcomes after vitrectomy. A recent report by Chang given at the LXII (62) Edward Jackson Memorial Lecture hypothesized a causal relationship between vitrectomy and open-angle glaucoma (OAG) via oxidative stress exacerbated by removal of the crystalline lens. A second report by Luk and colleagues reported similar conclusions in a modified cohort. Both studies, were retrospective in nature and did not perform baseline evaluations to exclude pre-existing glaucoma. Furthermore neither study accounted for natural history. Finally, our analysis has not reproduced similar results.

The primary purpose of this study is to analyze the full spectrum of optic nerve and macular changes between vitrectomized study eyes and their non-vitrectomized fellow eyes to control for natural history. Baseline evaluations will include examination by fellowship trained retina and glaucoma specialists, fundus photography, autofluorescence, optical coherence tomography (macula and optic nerve) and automated visual field testing. At 3 month then annually for 5 years after vitrectomy surgery, the cohort will undergo similar evaluation.

Condition or disease
Glaucoma Macular Pucker Macula Hole Vitreomacular Traction Vitreous Opacities or Hemorrhage

Layout table for study information
Study Type : Observational
Actual Enrollment : 45 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Analysis of Nerve Fiber Layer and Macular Changes After Pars Plana Vitrectomy
Actual Study Start Date : July 2010
Actual Primary Completion Date : January 24, 2017
Actual Study Completion Date : January 24, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Primary Outcome Measures :
  1. Nerve fiber layer and macular changes after vitrectomy [ Time Frame: 3 month and annually for 5 years after surgery ]
    To determine the incidence of nerve fiber layer (NFL) and macular changes after pars plana vitrectomy, characterize their extent and quality, and determine pre-disposing risk factors.

Secondary Outcome Measures :
  1. Visual field defects [ Time Frame: 3 month and annually for 5 years after surgery ]
    To characterize long-term functional consequences of NFL or macular changes with regards to peripheral and central visual field defects after PPV.

  2. Open-angle glaucoma [ Time Frame: 3 month and annually for 5 years after surgery ]
    To determine the incidence of elevated intraocular pressure and open-angle glaucoma following vitrectomy. Enrolled patients will be screened at baseline to exclude pre-existing glaucoma and post-operative glaucoma screenings will be performed by fellowship trained glaucoma specialist.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adult patients presenting to ophthalmology practice requiring pars plana vitrectomy

Inclusion Criteria:

  • Able to consent and comply for the duration of the study and imaging studies
  • Media clarity sufficient for imaging studies
  • No previous treatment or surgery that might confound study results in the study or fellow eye
  • Pars plana vitrectomy (PPV) indicated for epiretinal membrane (ERM), macular hole (MH), vitreo-macular traction (VMT), and vitreous hemorrhage (VH)

Exclusion Criteria:

  • Unable to consent and/or comply for the duration of the study and imaging studies
  • History of the following conditions: Glaucoma or associated conditions, visual field defects, uveitis, age-related macular degeneration (ARMD), prior PPV for retinal detachment, retained lens or dislocated intraocular lens
  • Contralateral eye status post PPV or with advanced eye disease serious enough to warrant future PPV - Contralateral eye with condition that may result in choroidal neovascular membrane

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01162356

Layout table for location information
United States, Tennessee
Vanderbilt Eye Institute
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Vanderbilt University
Layout table for investigator information
Principal Investigator: Stephen J Kim, MD Vanderbilt Eye Institute
Study Director: Maziar Lalezary, MD Vanderbilt Eye Institute
Study Director: Rahul K Reddy, MD Vanderbilt Eye Institute
Layout table for additonal information
Responsible Party: Stephen J. Kim, MD, Associate Professor of Ophthalmology, Vanderbilt University
ClinicalTrials.gov Identifier: NCT01162356    
Other Study ID Numbers: 100073
First Posted: July 14, 2010    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017
Keywords provided by Stephen J. Kim, MD, Vanderbilt University:
Optic nerve
Ocular Coherence Tomography
Additional relevant MeSH terms:
Layout table for MeSH terms
Epiretinal Membrane
Ocular Hypertension
Eye Diseases
Pathologic Processes
Retinal Diseases